Sale
Massive Discounts! Up to 30% OFF on reports🎉

Soft Tissue Sarcoma Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Soft Tissue Sarcoma Market is segmented by Disease Type (Local sarcoma, Regional sarcoma, Metastatic sarcoma), by Treatment (Radiation Therapy, Chemotherapy, Targeted therapy, Anti-angiogenesis drugs, and Other Treatments), By End-User (Hospitals, Oncology Centers and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Published: December 2024 || SKU: PH356
excelpdfpowerpoint
180 pages
Report Summary
Table of Contents
List of Tables & Figures
Download Free Sample

Market Overview

Global Soft Tissue Sarcoma market is expected to grow at a CAGR of 8.8% during the forecast period 2024-2031.

  • Increasing prevalence of soft tissue sarcoma, rising Research and Development activities on drugs and other therapies, are some of the growth factors boosting the growth of the market. Soft tissue sarcoma is a type of cancer that grows from tissues such as nerves, muscles, fats, blood vessels, and thick skin tissues.
  • There are around 50 different types of soft tissue sarcoma, such as adult fibrosarcoma, angiosarcoma, clear cell sarcoma, alveolar soft-part sarcoma, Kaposi sarcoma, malignant mesenchymoma, rhabdomyosarcoma, and others. There are several drugs used for the treatment of soft tissue sarcomas such as sunitinib (Sutent), trabectedin (yondelis), sirolimus (Rapamune), bevacizumab (Avastin), doxorubicin (adriamycin), and others.

Market Scope

MetricsDetails
Market CAGR8.8%
Segments Covered By Disease Type, By Treatment, By End User, and By Region
Report Insights CoveredCompetitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
Fastest Growing RegionAsia Pacific
Largest Market Share North America

For more insights - Request free Sample

 

Market Dynamics

  • In Oct 2016, U.S. Food and Drug Administration approved Eli Lilly and Company's drug Lartruvo (Olaratumab) with Doxorubicin to treat certain types of soft tissue carcinoma.Clinical Trial Analysis:Total Soft Tissue Sarcoma Studies: 1567
  • By Disease Type, the market is segmented into Local sarcoma, Regional sarcoma, and Metastatic sarcoma. By treatment type, the soft tissue sarcoma market is segmented into radiation therapy, targeted therapy, chemotherapy, anti-angiogenesis drugs, and Others.
  • Chemotherapy has the largest market share in the soft tissue sarcoma market. Further, by End-user, the market has been segmented into hospitals, oncology centers, and Others. Hospitals are dominating the global soft tissue sarcoma market during the forecast period due to increasing number of patients getting treatment at hospitals for soft tissue sarcoma and other relevant cancers.

Geographical Shares

  • Geographically, the market is segmented into North America, South America, Europe, Asia-Pacific, and RoW. North America is leading the global soft tissue sarcoma market due to the high prevalence of cancer and soft tissue sarcoma. According to the American Cancer Society, there were more than 11,500 new cases of soft tissue sarcoma were diagnosed in the U.S. in 2014. Asia-Pacific region is also growing due to rising awareness about increasing advanced treatments for cancer.
  • The major players of global Soft Tissue Sarcoma market include GlaxoSmithKline plc, Eli Lilly and Company, Pfizer, Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche AG (Genentech), Johnson & Johnson Services, Teva Pharmaceutical Industries Ltd Celgene Corporation, and others.
  • Some recently approved drugs for the treatment of Soft Tissue Sarcoma are:
  • In June 2018, Taiwan Liposome Company, (TLC), a clinical-stage specialty pharmaceutical company declared the submission of an Investigational New Drug (IND) application with the U. S. FDA to initiate a Phase I/II, open-label, dose-escalation clinical trial of TLC178, a NanoX liposomal formulation of the anticancer drug vinorelbine, in pediatric rhabdomyosarcoma (a type of soft tissue sarcoma) patients.
  • The report covers the factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles.
Buy this report
Single User
$4350
Multiple User
$4850
Enterprise User
$7850
Proceed to Buy
  Get Free Sample
  Request new version
  Customize Sample
  Demo Full Report
FAQ’s

  • Major players are Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Pfizer Inc, Johnson & Johnson Services Inc, Teva Pharmaceutical Industries Ltd, Celgene Corporation, Bristol-Myers Squibb Company, Threshold Pharmaceuticals Inc, and Merck KGaA.

  • Global Soft Tissue Sarcoma market is expected to grow at a CAGR of 8.8% during the forecast period 2024-2031.
Related Reports
pharmaceuticals iconpharmaceuticals

Tyrosine Kinase Inhibitors Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 September 12

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Chemotherapy Induced Anemia Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 January 11

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Chronic Lymphocytic Leukemia Therapeutics Market Size, Share Analysis, Value and Forecast (2024-2031)

Published: 2024 November 13

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Oncolytic Virus Therapy Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 November 25

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Oncology Nutrition Market Size, Share, Growth Insights and Forecast 2025-2033

Published: 2025 February 11

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Hepatocellular Carcinoma Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 December 10

Starting from

$4350